BioInformatics, LLC New Report – Capitalizing on New Opportunities for Stem Cell Products

ARLINGTON, VA, April 7, 2009 – BioInformatics, LLC announces the pending release of its newest report, Capitalizing on New Opportunities for Stem Cell Products. As a result of the March 9, 2009 reversal of the 2001 restrictions on federal funding of human embryonic stem cell research, suppliers of stem cell related products are in need of a fast, accurate assessment of new opportunities in the stem cell products market. In this report, BioInformatics, LLC (http://www.gene2drug.com), the premier research and advisory firm serving the life science market, fielded a detailed 60-question survey to scientists worldwide about their current—and planned—areas of stem cell research, usage of stem cell products and preferred suppliers.

The report is scheduled to release at the end of April, and is available at pre-release pricing until May 17, 2009. This special pricing is at a significant reduction off the regular pricing which will take effect on Monday, May 18, 2009.

Scientists involved in stem cell research, whether they are more focused on understanding basic stem cell biology, developing cell-based therapies using stem cells, or using stem cells to improve drug target validation and toxicology screening, rely on stem cell research products from major life science suppliers as well as more niche stem cell companies. In this report, scientists specify percentage of stem cell culture products purchased from each of the following suppliers:

ATCC
BD Biosciences (a part of Becton, Dickinson and Co., NYSE:BDX)
CellGenix
Life Technologies (NASDAQ: LIFE)
Lonza (SWX: LONN)
Millipore (NYSE: MIL)
Miltenyi Biotec
R&D Systems (division of TECHNE Corp., NASDAQ: TECH)
Sigma-Aldrich (divisions: SAFC Biosciences, NASDAQ: SIAL)
Stem Cell Sciences (AIM: STEM)
Stemcell Technologies
Thermo Fisher Scientific (Hyclone, NYSE: TMO)
Zen Bio

Life science suppliers can use this study to determine areas poised for growth (i.e., media, sera, supplements and cell lines) in the stem cell research products market, identify potential key competitors (including percentage of products purchased from each major supplier), and plan a long-term strategy to secure a leading position in this expanding market. The report includes detailed market share estimates across major stem cell product categories by market segment, geographic region and top suppliers.

“There is tremendous excitement, especially in the academic community, over the recent Executive Order signed by President Barack Obama rescinding the restriction on federal funding of human embryonic stem cell research,” notes Tamara Zemlo, Ph.D., MPH, Vice President of Advisory Services. “However, the exploration of induced pluripotent stem cells and the pursuit of cell-based therapies and drug discovery and development research using adult human stem cells continues to provide great promise.” Dr. Zemlo has been the senior analyst on over 80 syndicated market research reports, and consulted with multiple stem cell product vendors to optimize the relevance of this study with regards to the current stem cell research market. According to Zemlo, the report provides insights into the origins and sources of stem cells currently used in the lab (adult, embryonic, induced and pluripotent), and those likely to be used over the next several years—in addition to differentiated cell types and associated diseases under investigation—allowing suppliers to anticipate the types of stem cell culture products labs will need to purchase.

To learn more about this report, a complimentary Executive Summary is available at http://www.gene2drug.com/reports/201/.

ABOUT BIOINFORMATICS, LLC

BioInformatics, LLC is the premier research and advisory firm serving the life science industry. By leveraging our professional social network of more than 42,000 biomedical researchers, we have supported more than 300 companies and provided insights that lead to better business decisions. Our assignments include assessing the size and attractiveness of markets, optimizing product configurations and pricing, validating corporate acquisitions, measuring customer loyalty, and evaluating brand strength and positioning.

Mary Follin
Manager, Marketing/Sales
BioInformatics, LLC
2111 Wilson Blvd., Suite 250
Arlington, VA 22201
703.778.3080 x13 (phone)
m.follin@gene2drug.com
http://www.gene2drug.com/

This release was published on openPR.